Vertex Pharmaceuticals Incorporated (ETR:VX1)
392.60
-0.05 (-0.01%)
Jun 10, 2025, 4:43 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
9.89
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
101.55B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Vertex Pharmaceuticals News
- 1 day ago - Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga
- 4 days ago - Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Wallstreet:Online
- 4 days ago - Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Business Wire
- 11 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 13 days ago - 3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow - The Motley Fool
- 18 days ago - Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? - Seeking Alpha
- 21 days ago - Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga
- 21 days ago - Vertex Pharma announces new share buybacks worth up to $4B - Seeking Alpha